CE-Ventures leads the final close of the $26mln Series A funding round for Exeliom Biosciences to advance pipeline-in-a-drug strategy

CE-Ventures leads the final close of the $26mln Series A funding round for Exeliom Biosciences to advance pipeline-in-a-drug strategy

Financing will enable several Phase 1/2 studies of EXL01 in combination with standard-of-care treatments in immuno-oncology CE-Ventures, the corporate venture capital platform of Crescent Enterprises, a leading global, diversified business headquartered in the UAE, announced that it successfully led the extension to the Series A funding round totalling US$26 million in Exeliom Biosciences, a France-based, clinical-stage biopharmaceutical company specialised in the development of microbiome-based immunotherapies. Exeliom Biosciences is on a mission to bring innovation to the pharmaceutical treatment of inflammatory bowel diseases, cancer, and infectious diseases. The microbiome consists of all living organisms - including microbes, bacteria, protozoa, and fungi, that reside in and on the human body, mostly in the gastrointestinal tract and on the skin. The human microbiome market is projected to reach US$3.1 billion by 2029 from US$600 million in 2021, at a CAGR of 23%. The capital raised will be used primarily to progress the clinical development of Exeliom Biosciences’ lead candidate EXL01 in Immuno-Oncology. EXL01 is a, once-daily, potentially first-in-class, microbiome-based immunotherapy containing a well-characterised, unmodified, single-strain of the major dominant commensal bacterium Faecalibacterium prausnitzii (F. prausnitzii). In the rapidly expanding field of microbiome-based therapeutics, interest has turned to identifying specific strains of bacteria that